Dr. Kahl on Ibrutinib in CLL

Video

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

In 2016, ibrutinib was FDA approved for the frontline treatment of CLL. Now, any patient can receive that therapy, which gives physicians more options to consider. Ibrutinib is very active in CLL and has demonstrated high response rates in addition to durable remissions, says Kahl. However, the BTK inhibitor is administered as a chronic daily therapy, whereas other therapies have a finite duration of administration, notes Kahl.

Patients who receive the fludarabine-cyclophosphamide-rituximab regimen or bendamustine plus rituximab (Rituxan) can anticipate coming off therapy, whereas patients on ibrutinib have to continue therapy indefinitely. Physicians do not yet have the comparative data to say that one is better than the other, adds Kahl. Therefore, deciding whether to pursue ibrutinib or an alternative regimen is something that should be discussed on an individualized basis.

Related Videos
Jennifer Brown, MD, PhD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania